Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mankind pharma launched Molulife (Molnupiravir) developed by MSD and Ridgeback Biotherapeutics by next week, It is also expected that Cipla, Sun pharma, and DRL will also release Molnupiravir in the coming weeks for the treatment of patients with severe ...
Product Name : Molulife
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2022
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Panacea Biotec Limited
Deal Size : $251.1 million
Deal Type : Agreement
Panacea Biotec Sells Domestic Formulation Assets To Mankind Pharma for Rs 1,908 Crore
Details : The top selling brands are Pangraf (tacrolimus), Alphadol (alfacalcidol), Cilamin (penicillamine) & Livoluk Fibre (lactulose in combination with ispaghula) were ranked number 1, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were...
Product Name : Pangraf
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 02, 2022
Lead Product(s) : Tacrolimus
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Panacea Biotec Limited
Deal Size : $251.1 million
Deal Type : Agreement
Lead Product(s) : Posaconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mankind Pharma Launches Drug to Treat Black Fungus
Details : Posaconazole has been found to be a safer and effective drug of choice for the management of the disease. The drug has received approval from the Drug Controller General of India (DCGI).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : Posaconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 2-Deoxy-D-Glucose
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mankind Pharma Gets DRDO Nod to Manufacture, Market Covid Drug 2-DG
Details : 2-DG (2-deoxy-D-glucose) is approved and is indicated as an adjunct treatment for patienst siffering from moderate to severe Covid-19.
Product Name : 2-DG
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2021
Lead Product(s) : 2-Deoxy-D-Glucose
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mankind Pharma Launches Justoza to Treat Diabetes, Heart Failure & CKD
Details : Mankind Pharma has launched Justoza, a Dapagliflozin brand marketed by Mankind to treat diabetes, heart failure and chronic kidney disease. Launching API DMF grade dapagliflozin is an innovative futuristic approach to provide the best in class quality to...
Product Name : Justoza
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2021
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MKP10241
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mankind Pharma Gets CDSCO Panel Nod for Phase I Trial of Anti-Diabetic Drug, MKP10241
Details : MKP10241, a new class of anti-diabetic molecules, is designed and developed at the Mankind Research Centre. It is a potent and orally administered small molecule, GPR119 agonist. GPR 119 is highly expressed in pancreatic beta cells and intestinal enteroe...
Product Name : MKP10241
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2021
Lead Product(s) : MKP10241
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Technosphere Insulin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company announced that new data from clinical studies of Afrezza® demostrating safe and effective dosing, its association with weight loss in patients with type 2 diabetes, and an evaluation of a comprehensive two year safety study showing that signific...
Product Name : Afrezza
Product Type : Hormone
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Technosphere Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KEY PRODUCTS
Reset All
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
